The nation of Zimbabwe has turned down a major American health deal worth $367m (£272m) spanning five years because of Washington's insistence on confidential biological samples.
The decision was revealed following a internal memorandum from December was disclosed, which showed Head of State Emmerson Mnangagwa felt the arrangement was "unbalanced".
A government representative later explained that the US was demanding access to genetic material for scientific study and profit while was not willing to guarantee the benefits from future medical innovations.
"We are forced to start the challenging and unfortunate task of ending our support in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy noted the United States had provided over $1.9bn as health assistance to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has called for further dialogue to reach a deal acceptable to all parties so the country's critical HIV programme can proceed.
Wider Implications
Zimbabwe's decision comes after a comparable situation in Kenya, where a court halted a similar health funding agreement following legal challenges were filed about the safety of citizens' health data.
After returning to the presidency last year, US President Donald Trump has drastically cut foreign aid and closed the US Agency for International Development (USAID).
The agency had administered aid for the American government, but Trump argued its expenditure was "inefficient" and his administration was pursuing government-to-government deals to enhance transparency and accountability.
Based on statements, Sixteen African countries have so far signed similar agreements, constituting over $18.3bn of fresh investment.
Specifics of the Declined Deal
This assistance for Zimbabwe was intended to gone towards "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"It is our view this collaboration would have delivered significant benefits for the people of Zimbabwe, particularly the 1.2 million men, women and children presently on HIV treatment via American-funded programmes," Tremont added.
However, official spokesman Nick Mangwana said the proposed deal was "unequal".
"Our nation was requested to surrender its biological resources and data over an extended period, without any corresponding guarantee of access to any medical innovations – such as vaccines, diagnostics, or treatments – that could be developed from that provided information," Mangwana explained.
"Put simply, our nation would supply the basic resources for scientific discovery with no assurance that the resulting innovations would be available to our citizens if a future pandemic arise."
National Interest and Global Health
Mangwana further noted that the American exit from the global health body and its pursuit of bilateral deals were disrupting structures already established through the international health agency.
The spokesperson cited its Pathogen Access and Benefit Sharing framework designed to manage future global health emergencies.
"This system is intended to guarantee that when a country contributes its samples, the resulting advantages – including medicines and cures – are shared equitably, not commercialised solely by those with the capability to develop them."
Zimbabwe's reservations regarding the US deal "are not meant as hostility towards the US," he added.
"We welcome further discussions with our US partners on how subsequent collaboration could be structured in a manner that respects the independence and interests of both nations."
Medical Community Response
The Zimbabwe College of Public Health Physicians (ZCPHP) said it acknowledged the official position, but urged that talks must proceed considering a large portion of the nation's Aids initiatives were funded by foreign aid.
"If technical issues exist, such as those relating to data governance or implementation frameworks, these can frequently be addressed via detailed discussion and negotiated safeguards," it said.
This impasse highlights the ongoing tensions between receiving crucial international aid and protecting local interests in an increasingly data-driven world.